MY150797A - Combination therapies comprising quinaxoline inhibitors of pi3k-alpha for use in the treatment of cancer - Google Patents

Combination therapies comprising quinaxoline inhibitors of pi3k-alpha for use in the treatment of cancer

Info

Publication number
MY150797A
MY150797A MYPI20094215A MY150797A MY 150797 A MY150797 A MY 150797A MY PI20094215 A MYPI20094215 A MY PI20094215A MY 150797 A MY150797 A MY 150797A
Authority
MY
Malaysia
Prior art keywords
cancer
quinaxoline
pi3k
inhibitors
alpha
Prior art date
Application number
Other languages
English (en)
Inventor
Lamb Peter
Matthews David
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of MY150797A publication Critical patent/MY150797A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI20094215 2007-04-11 2008-04-08 Combination therapies comprising quinaxoline inhibitors of pi3k-alpha for use in the treatment of cancer MY150797A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92316407P 2007-04-11 2007-04-11

Publications (1)

Publication Number Publication Date
MY150797A true MY150797A (en) 2014-02-28

Family

ID=39864581

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20094215 MY150797A (en) 2007-04-11 2008-04-08 Combination therapies comprising quinaxoline inhibitors of pi3k-alpha for use in the treatment of cancer

Country Status (33)

Country Link
US (1) US8481001B2 (enExample)
EP (1) EP2139483B9 (enExample)
JP (2) JP5726515B2 (enExample)
KR (1) KR101586774B1 (enExample)
CN (2) CN101959516B (enExample)
AU (1) AU2008239668B2 (enExample)
BR (1) BRPI0810208A2 (enExample)
CA (1) CA2684056A1 (enExample)
CO (1) CO6140024A2 (enExample)
CR (1) CR11099A (enExample)
CY (1) CY1114608T1 (enExample)
DK (1) DK2139483T3 (enExample)
EA (1) EA019064B1 (enExample)
EC (1) ECSP099723A (enExample)
ES (1) ES2438998T3 (enExample)
GT (1) GT200900263A (enExample)
HR (1) HRP20131081T1 (enExample)
IL (1) IL201211A (enExample)
MA (1) MA31335B1 (enExample)
ME (1) ME00937B (enExample)
MX (1) MX2009010929A (enExample)
MY (1) MY150797A (enExample)
NI (1) NI200900184A (enExample)
NZ (1) NZ580009A (enExample)
PL (1) PL2139483T3 (enExample)
PT (1) PT2139483E (enExample)
RS (1) RS53020B (enExample)
SI (1) SI2139483T1 (enExample)
SV (1) SV2009003390A (enExample)
TN (1) TN2009000399A1 (enExample)
UA (1) UA98141C2 (enExample)
WO (1) WO2008127594A2 (enExample)
ZA (1) ZA200906765B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ594628A (en) * 2005-10-07 2013-04-26 Exelixis Inc PYRIDOPYRIMIDINONE INHIBITORS OF PI3Ka
RS53627B1 (sr) * 2005-10-07 2015-04-30 Exelixis Inc. Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova upotreba kao inhibitora fosfatidilinozitol3-kinaze
WO2008021389A2 (en) 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
RS52939B (sr) * 2007-04-10 2014-02-28 Exelixis Inc. Postupci za lečenje kancera upotrebom piridopirimidinonskih inhibitora pi3k alfa
EP2374802B1 (en) 2008-11-10 2014-04-23 Kyowa Hakko Kirin Co., Ltd. Kynurenine production inhibitor
DE102009049679A1 (de) 2009-10-19 2011-04-21 Merck Patent Gmbh Pyrazolopyrimidinderivate
AR080151A1 (es) 2010-02-09 2012-03-14 Exelixis Inc Metodos para tratar cancer usando inhibidores de piridopirimidinona de pi 3k y mtor en combinacion con inhibidores de autofagia
CA2803900A1 (en) 2010-07-09 2012-01-12 Exelixis, Inc. Combinations of kinase inhibitors for the treatment of cancer
JP5792819B2 (ja) 2010-09-14 2015-10-14 エクセリクシス， インク． Ｐｉ３ｋ−デルタの阻害剤ならびにそれらの使用法および製造法
DE102010048800A1 (de) * 2010-10-20 2012-05-10 Merck Patent Gmbh Chinoxalinderivate
JP2013540141A (ja) 2010-10-20 2013-10-31 メルク セローノ ソシエテ アノニム ジュネーブ 置換ｎ−（３−アミノ−キノキサリン−２−イル）−スルホンアミドおよびそれらの中間体ｎ−（３−クロロ−キノキサリン−２−イル）スルホンアミドを調製する方法
DE102010049595A1 (de) 2010-10-26 2012-04-26 Merck Patent Gmbh Chinazolinderivate
WO2012065057A2 (en) 2010-11-12 2012-05-18 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors and methods of their use
AU2012308414A1 (en) * 2011-09-14 2014-05-01 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors for the treatment of cancer
US20140235643A1 (en) * 2011-10-04 2014-08-21 Gilead Calistoga Llc Novel quinoxaline inhibitors of pi3k
WO2013056067A1 (en) 2011-10-13 2013-04-18 Exelixis, Inc. Compounds for use in the treatment of basal cell carcinoma
CA2853095A1 (en) * 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
EA201490905A1 (ru) * 2011-11-01 2014-11-28 Экселиксис, Инк. N-(3-{[(3-{[2-хлор-5-(метокси)фенил]амино}хиноксалин-2-ил)амино]сульфонил}фенил)-2-метилаланинамид как ингибитор фосфатидилинозитол-3-киназы для лечения лимфопролиферативных злокачественных заболеваний
WO2013067306A1 (en) * 2011-11-02 2013-05-10 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors for the treatment of childhood cancers
JP2015503568A (ja) * 2011-12-27 2015-02-02 カドモン コーポレイション，リミティド ライアビリティ カンパニー トラスツズマブに不応性の乳癌の治療方法
JP6077642B2 (ja) 2012-04-10 2017-02-08 シャンハイ インリ ファーマシューティカル カンパニー リミティド 縮合ピリミジン化合物、その調製法、中間体、組成物、及び使用
JP6193374B2 (ja) 2012-08-13 2017-09-06 武田薬品工業株式会社 Ｇｐｒ６モジュレーターとしてのキノキサリン誘導体
EP3053926B1 (en) 2013-09-30 2018-08-08 Shanghai Yingli Pharmaceutical Co. Ltd. Fused pyrimidine compound, intermediate, preparation method therefor, and composition and application thereof
JP6139789B2 (ja) 2013-10-16 2017-05-31 シャンハイ インリ ファーマシューティカル カンパニー リミティド 縮合複素環化合物、その調製方法、医薬組成物及びその使用
WO2015123505A1 (en) 2014-02-14 2015-08-20 Takeda Pharmaceutical Company Limited Pyridopyrazines modulators of gpr6
US9950194B2 (en) 2014-09-09 2018-04-24 Mevion Medical Systems, Inc. Patient positioning system
WO2019119206A1 (en) * 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006515885A (ja) * 2003-01-17 2006-06-08 スレッシュオールド ファーマシューティカルズ， インコーポレイテッド 癌の処置のための併用療法
EA015937B1 (ru) * 2005-08-26 2011-12-30 Мерк Сероно С.А. Производные пиразина и их применение в качестве ингибиторов pi3k
NZ594628A (en) 2005-10-07 2013-04-26 Exelixis Inc PYRIDOPYRIMIDINONE INHIBITORS OF PI3Ka
RS53627B1 (sr) 2005-10-07 2015-04-30 Exelixis Inc. Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova upotreba kao inhibitora fosfatidilinozitol3-kinaze
WO2008021389A2 (en) * 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
EP2118076B1 (en) * 2007-02-22 2019-09-04 Merck Serono S.A. Quinoxaline compounds and use thereof
RS52939B (sr) 2007-04-10 2014-02-28 Exelixis Inc. Postupci za lečenje kancera upotrebom piridopirimidinonskih inhibitora pi3k alfa
JP4623164B2 (ja) * 2008-08-21 2011-02-02 セイコーエプソン株式会社 プロジェクタ

Also Published As

Publication number Publication date
AU2008239668A1 (en) 2008-10-23
KR20100019436A (ko) 2010-02-18
ZA200906765B (en) 2010-05-26
RS53020B (sr) 2014-04-30
TN2009000399A1 (fr) 2010-12-31
CN101959516A (zh) 2011-01-26
MA31335B1 (fr) 2010-04-01
CA2684056A1 (en) 2008-10-23
MX2009010929A (es) 2010-01-20
ME00937B (me) 2012-06-20
BRPI0810208A2 (pt) 2014-10-21
EA200970935A1 (ru) 2010-04-30
KR101586774B1 (ko) 2016-01-19
AU2008239668B2 (en) 2013-11-07
IL201211A (en) 2015-09-24
ECSP099723A (es) 2010-03-31
DK2139483T3 (da) 2014-01-13
GT200900263A (es) 2014-01-15
EP2139483A2 (en) 2010-01-06
WO2008127594A3 (en) 2009-04-30
ES2438998T3 (es) 2014-01-21
US8481001B2 (en) 2013-07-09
EA019064B1 (ru) 2013-12-30
NZ580009A (en) 2012-06-29
JP2010523669A (ja) 2010-07-15
HRP20131081T1 (hr) 2013-12-20
PT2139483E (pt) 2013-12-27
SI2139483T1 (sl) 2013-11-29
US20110123434A1 (en) 2011-05-26
EP2139483B1 (en) 2013-09-18
CN101959516B (zh) 2013-05-08
CO6140024A2 (es) 2010-03-19
UA98141C2 (ru) 2012-04-25
JP5726515B2 (ja) 2015-06-03
CN103202842A (zh) 2013-07-17
PL2139483T3 (pl) 2014-02-28
CR11099A (es) 2010-01-19
NI200900184A (es) 2011-09-08
HK1140141A1 (en) 2010-10-08
WO2008127594A2 (en) 2008-10-23
IL201211A0 (en) 2010-05-31
CY1114608T1 (el) 2016-10-05
JP2014074031A (ja) 2014-04-24
EP2139483B9 (en) 2014-05-21
SV2009003390A (es) 2010-05-21

Similar Documents

Publication Publication Date Title
MY150797A (en) Combination therapies comprising quinaxoline inhibitors of pi3k-alpha for use in the treatment of cancer
TN2009000400A1 (en) Methods of treating cancer using pyridopyrimidininone inhibitors of pi3k alpha
TN2012000622A1 (en) Combinations of kinase inhibitors for the treatment of cancer
TW200738725A (en) Unsaturated mTOR inhibitors
MX2009009786A (es) Inhibidores de la via de hedgehog.
MY146111A (en) Acylaminopyrazoles as fgfr inhibitors
TR201900306T4 (tr) Mek inhibitörlerini kullanma yöntemleri.
JO2886B1 (en) Useful compounds in the inhibition of CHK1
MY179607A (en) Combinations of akt inhibitor compounds and abiraterone, and methods of use
MY148688A (en) 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
TW200740776A (en) N-phenylbenzotriazolyl c-kit inhibitors
MX378263B (es) Terapia de combinación para el tratamiento del cáncer.
NZ590550A (en) Inhibitors of Apoptosis (IAP) for treating cancer
MX2010010300A (es) Formas de sal de inhibidores del objetivo de rapamicina en mamiferos.
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
MX2014003180A (es) Metodos para tratar vhc.
SG10201810401RA (en) Pharmaceutical combinations for treating cancer
TW200722083A (en) Combinations and methods of using an indolinone compound
MX2010004967A (es) Uso de inhibidor de cfms para el tratamiento y la prevención del cancer de hueso, así como la perdida osea y el dolor de hueso asociados con el cancer de hueso.
UA96969C2 (en) Acylaminopyrazoles as fgfr inhibitors
JO3145B1 (ar) مركبات مفيدة لتثبيط chk1
EA200870454A1 (ru) Способ ингибирования c-kit киназы
MX2011011687A (es) Flavonas sustituidas de pirrolidina como sensibilizadores de radio para su uso en el tratamiento del cancer.
IN2012DN02816A (enExample)
WO2007136615A3 (en) Combination cancer therapy